Effect of administration route on the biodistribution of albumin microspheres labelled with Re-188

«Radiation and Risk», 2021, vol. 30, No. 4, pp.85-93

DOI: 10.21870/0131-3878-2021-30-4-85-93

Authors

Tishchenko V.K. – Lead. Researcher, C. Sc., Biol.
Petriev V.M. – Head of Lab., D. Sc., Biol., Prof. of MEPhI. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: (484) 399-71-00; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Vlasova O.P. – Lead. Researcher, C. Sc., Biol.
Stepchenkova E.D. – Junior Researcher. A. Tsyb MRRC.
¹ A. Tsyb MRRC, Obninsk
² National Research Nuclear University MEPhI, Moscow

Abstract

Nowadays the radiolabeled microspheres are established tools for radioembolization of primary and metastatic liver cancer. Human serum albumin microspheres (HSA) are unique carriers for selective and controlled radionuclide delivery to malignant tumors. Rhenium-188 (¹⁸⁸Re), which decays with beta particles (2.12 MeV (71.1%) and 1.965 MeV (25.6%) and gamma emission (155 keV (15.1%)) is one of the most available and promising generator-based radionuclide for cancer therapy. The purpose of this work was to study the biodistribution of microspheres based on human serum albumin labeled with ¹⁸⁸Re (¹⁸⁸Re-HSA) in animals after different routes of administration. The size of more than 95% of microspheres was 10-20 μm. The studies were carried out on outbred white mice and inbred C57BL/6 mice with transplanted Lewis adenocarcinoma after intravenous, intramuscular and intratumoral administration. After intravenous injection the highest amount of ¹⁸⁸Re-HSA in organs and tissues was observed: up to 311.3%/g in lungs, up to 74.30%/g in thyroid gland, up to 12.70%/g in liver, up to 0,81%/g in blood. After the intramuscular injection of ¹⁸⁸Re-HSA, the concentration of ¹⁸⁸Re-HSA in organs and tissues was significantly lower and did not exceed 1%/g, except for thyroid gland (1,10-17.80%/g). After intratumoral injection the amount of ¹⁸⁸Re-HSA in tumor varied from 16.7 to 26.8%/g, that was higher as compared with other organs and tissues. Thus, the routes of ¹⁸⁸Re-HSA administration significantly affect its behavior in the body. The obtained results can be used to evaluate the ¹⁸⁸Re-HSA potential for radionuclide tumor therapy after intravascular or intratumoral administration.

Key words
microspheres, human serum albumin, rhenium-188, radionuclide therapy, cancer diseases, intramuscular injection, intratumoral injection.

References

1. Bouvry C., Palard X., Edeline J., Ardisson V., Loyer P., Garin E., Lepareur N. Transarterial radioembolization (TARE) agents beyond 90Y-microspheres. BioMed. Res. Int., 2018, vol. 2018, pp. 1-14.

2. Li R., Li D., Jia G., Li X., Sun G., Zuo C. Diagnostic performance of theranostic radionuclides used in transarterial radioembolization for liver cancer. Front. Oncol., 2021, vol. 10, pp. 551622.

3. Bozkurt M.F., Salanci B.V., Ugur Ö. Intra-arterial radionuclide therapies for liver tumors. Semin. Nucl. Med., 2016, vol. 46, no. 4, pp. 324-339.

4. Reinders M.T.M., Smith M.J.L., van Roekel C., Braat A.J.A. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin. Nucl. Med., 2019, vol. 49, no. 3. pp. 237-243.

5. Zverev A.V., Klement’eva O.E., Zhukova M.V., Krasnoperova A.S. Preclinical evaluation of therapeutic potential of radiopharmaceutical based on albumin microspheres, 5-10 μm, labeled with rhenium-188. Russkiy meditsinskiy zhurnal – Russian Medical Journal, 2018, no. 4(I), pp. 31-35. (In Russian).

6. Vimalnath K.V., Chakraborty S., Rajesmari A., Sarma H.D., Nuwad J., Pandey U., Kamaleshwaran K., Shinto A., Dash A. Radiochemistry, pre-clinical studies and first clinical investigation of 90Y-labeled hydroxyapatite (HA) particles prepared utilizing 90Y produced by (n,γ) route. Nucl. Med. Biol., 2015, vol. 42, no. 5, pp. 455-464.

7. Dong Z., Meng X., Yang W., Zhang J., Sun P., Zhang H., Fang X., Wang D.A., Fan C. Progress of gelatin-based microspheres (GMSs) as delivery vehicles of drug and cell. Mater. Sci. Eng. C. Mater. Biol. Appl., 2021, vol. 122, pp. 111949.

8. Petriev V.M., Siryaev V.K., Smakhtin L.A., Skvortsov V.G. Development of a procedure for preparing 103Pd-microspheres of human blood albumin, a potential radiopharmaceutical for treatment of malignant tumors. Radiochemistry, 2010, vol. 52, no. 2, pp. 207-211.

9. Häfeli U.O., Casillas S., Dietz D.W., Pauer G.J., Rybicki L.A., Conzone S.D., Day D.E. Hepatic tumor radioembolization in a rat model using radioactive rhenium (186Re/188Re) glass microspheres. Int. J. Radiat. Oncol. Biol. Phys., 1999, vol. 44, no. 1, pp. 189-199.

10. Lin Y.C., Tsai S.C., Hung G.U., Lee J.C., Huang Y.S., Lin W.Y. Direct injection of 188Re-microspheres in the treatment of hepatocellular carcinoma. Compared with traditional percutaneous ethanol injection: an animal study. Nuklearmedizin, 2005, vol. 44, no. 3, pp. 76-80.

11. Wunderlich G., Pinkert J., Stintz M., Kotzerke J. Labeling and biodistribution of different particle materials for radioembolization therapy with 188Re. Appl. Radiat. Isot., 2005, vol. 62, no. 5, pp. 745-750.

12. Verger E., Drion P., Meffre G., Bernard C., Duwez L., Lepareur N., Couturier O., Hindré F., Hustinx R., Lacoeuille F. 68Ga and 188Re starch-based microparticles as theranostic tool for the hepatocellular carcinoma: radiolabeling and preliminary in vivo rat studies. PLoS One, 2016, vol. 11, no. 10, pp. e0164626.

13. Liepe K., Brogsitter C., Leonhard J., Wunderlich G., Hliscs R., Pinkrt J., Folprecht G., Kotzerke J. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. Jpn. J. Clin. Oncol., 2007, vol. 37, no. 12, pp. 942-950.

14. Nowicki M.L., Cwikla J.B., Sankowski A.J., Shcherbinin S., Grimmes J., Celle A., Buscombe J.R., Bator A., Pech M., Mikolajczak R., Pawlak D. Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers. Med. Sci. Monit., 2014, vol. 20, pp. 1353-1362.

15. Way of reception of microspheres labeled with radionuclide. Patent RU2359702C2, publication date 27.06.2009. (In Russian).

16. Petriev V.M. Regular trends in complexation of 188Re with human blood albumin microspheres. Radiochemistry, 2009, vol. 51, no. 5, pp. 510-516.

17. Besyadovskiy R.A., Ivanov K.V., Kozyura A.K. Reference guidance for radiobiologists. Moscow, Atomizdat, 1978. 128 p. (In Russian).

18. Petriev V.M., Siruk O.V., Bryukhanova A.A., Smoryzanova O.A., Skvortsov V.G. Pharmacokinetic characteristics of the radiopharmaceutical «188Re-albumin microspheres» after intravenous administration to laboratory animals. Pharm. Chem. J., 2014, vol. 47, no. 11, pp. 573-576.

19. Zuckier L.S., Dohan O., Li Y., Chang C.J., Carrasco N., Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J. Nucl. Med., 2004, vol. 45, no. 3, pp. 500-507.

Full-text article (in Russian)